Asthma accounted for a 13.4% share of the global clinical trials within the Respiratory therapy area in 2020, registering a decrease of 11.2% when compared with the last ten-year average of 24.6% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for Asthma
Industry sponsored trials held a 57.7% share of all the clinical trials for Asthma indication in 2020, registering an increase of 2.3% when compared with the ten-year average of 55.4%. Non-industry sponsored trials accounted for a 42.3% share in 2020, marking a decrease of 2.3% over the ten-year average of 44.6%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Asthma trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Asthma trials, accounting for a 61.7% share in 2020, when compared with the five-year average of 43.5% and ten-year average of 38.9%.
Europe was at the second position with a 33.6% share in 2020, over the five-year average of 54.3% and ten-year average of 54.7%, followed by North America with a 15.0% share in 2020, as against five-year and ten-year averages of 28.4% and 33.6% respectively.
Middle East and Africa stood fourth with a 4.7% share in 2020, compared with the five-year average of 8.7% and ten-year average of 9.4%, followed by South and Central America with a 3.7% share in 2020, over five-year and ten-year averages of 10.5% and 11.5% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for industry sponsored Asthma trials, accounting for a 39.3% share in 2020, as against the five-year average of 18.9% and ten-year average of 11.1%.
The US held a 14.0% share in 2020, over the five-year average of 26.3% and ten-year average of 30.3%, followed by Germany with a 9.3% share in 2020, compared with the five-year and ten-year averages of 21.6% and 21.9% respectively.
The UK held an 8.4% share in 2020, as against the five-year average of 18.0% and ten-year average of 19.1%.
Russia held an 8.4% share in 2020, over the five-year and ten-year averages of 16.8% and 16.6% respectively.
Top regions of non-industry sponsored Asthma trials
Asia-Pacific was the top region for non-industry sponsored Asthma trials, accounting for a 54.4% share in 2020 when compared with the five-year average of 43.8% and ten-year average of 42.1%.
Europe was at the second position with a 17.7% share in 2020, over the five-year and ten-year averages of 20.0% and 22.0% respectively, followed by Middle East and Africa with a 13.9% share in 2020, as against the five-year average of 14.2% and ten-year average of 12.7%.
North America stood at the fourth position with an 11.4% share in 2020, compared with the five-year average of 20.7% and ten-year average of 21.6%, followed by South and Central America with a 2.5% share in 2020, over the five-year and ten-year averages of 1.8% and 1.9% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Asthma trials, accounting for a 21.5% share in 2020, as against the five-year average of 10.3% and ten-year average of 9.9%.
India held a 17.7% share in 2020, over the five-year average of 14.6% and ten-year average of 10.7%, followed by Iran with a 12.7% share, compared with the five-year and ten-year averages of 12.2% and 10.1% respectively.
The US held an 8.9% share in 2020, as against the five-year average of 16.1% and ten-year average of 17.2%.
The UK held a 7.6% share in 2020, over the five-year average of 6.6% and ten-year average of 6.8%.
Phase I trials lead industry sponsored clinical trials for Asthma in 2020
Phase I trials held a 56.9% share of industry sponsored clinical trials for Asthma in 2020, over the five-year average of 39.0% and ten-year average of 36.6%.
Phase IV trials held a 20.7% share in 2020, as against the five-year average of 12.7% and ten-year average of 11.0%. Phase II trials held a 12.9% share in 2020, compared with the five-year and ten-year averages of 21.7% and 26.8% respectively.
Phase III trials held a 9.5% share in 2020, over the five-year average of 26.5% and ten-year average of 25.5%.
Phase IV trials lead non-industry sponsored clinical trials for Asthma in 2020
Phase IV trials held a 31.8% share of non-industry sponsored clinical trials for Asthma in 2020, over the five-year average of 25.5% and ten-year average of 27.0%.
Phase II trials held a 29.4% share in 2020, as against the five-year average of 50.8% and ten-year average of 49.9%. Phase III trials held a 25.9% share, compared with the five-year and ten-year averages of 16.9% and 15.2% respectively.
Phase I trials held a 12.9% share in 2020, over the five-year average of 6.8% and ten-year average of 7.9%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
